ADAGAdagene IncFinished
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
Advanced/Metastatic Solid Tumors
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jan 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 1/2
- Patients
- 58 (final count)
- Started
- Mar 15, 2021
- Main results expected
- Jan 29, 2024
- Fully finished
- May 17, 2024
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic solid tumors
Measured over: From first dose of ADG126 (Week 1 Day 1) until 21 days
Number of participants with adverse events as assessed by CTCAE v5.0 ADG126-ADG106 combination regimens
Measured over: From first dose of ADG126 (Week 1 Day 1) to 90 days post last dose
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-01-29, no fading
Raw record changes
- none yet
Trial ID NCT04645069 · record last updated 2024-08-14 · checked 2026-11-09 15:47 UTC